PremiumThe FlyMoody’s Investor Services upgrades Teva to Ba1 Teva upgraded to Overweight from Neutral at JPMorgan Positive Outlook for Teva Pharmaceutical: Cost-Cutting Initiatives and Growth Potential Drive Buy Rating PremiumThe FlyTeva, Alvotech: FDA approves interchangeability for SELARSDI with Stelara Teva, Alvotech announce FDA approval of interchangeability for SELARSDI Teva price target lowered to $20 from $24 at HSBC PremiumThe FlyTeva, Samsung Bioepis announce EPYSQLI availability in the U.S. Teva announces FDA acceptance of sBLA for AJOVY Positive Outlook for Teva Pharmaceuticals: Buy Rating Reiterated Amid Growth Initiatives and Improved Transparency 
